NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Scientists have developed a blood test that can detect motor neurone disease in its earliest stages with 97 per cent accuracy - even before symptoms strike. The test was developed by researchers at ...

Results from a randomized clinical trial have shown that a potential new treatment can help control the immune response of patients with motor neuron disease (MND), which could reduce further damage ...

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

A new medicine, discovered by scientists, protects nerve cells damaged by motor neurone disease (MND), offering hope of substantially slowing the progression of "one of the cruellest diseases".

Footballer Ezekiel Otuoma and his wife Rachael Otuoma. Otuoma died after a long battle with Motor Neurone Disease (MND). [File, Standard] Former AFC Leopards winger Ezekiel Otuoma passed away at the ...

The test was developed by researchers at the US-based not-for-profit Brain Chemistry Labs, who analysed 788 blood samples – roughly half from patients with the disease and half from people without it.